RNR News | Roxom Stocks

1 BTC

- USD

Loading market data...

Mkt Cap

$14.59B

Volume

239.32K

Next Earnings

October 27th

Mkt Cap

$14.30B

Volume

239.32K

Next Earnings

October 27th

Chart Financials Earnings News About Dividends Insider Filings

Will Chubb Limited Pull Off an Earnings Beat in the Third Quarter?Chubb Limited is expected to report Q3 2026 results on October 20 with revenues projected to rise 3.6% to $16.72 billion, but earnings are forecast to decline 12.8% to $6.53 per share. While premium growth, international expansion, and higher investment income should support results, catastrophe losses, softer property pricing, and rising expenses are expected to pressure profitability.Zacks Investment Research · Oct 16, 2026

FAF Trading at a Discount to Industry at 1.12X: Time to Buy or Hold?First American Financial (FAF) is trading at a valuation discount despite strong commercial title insurance demand, AI-driven operational efficiencies, and growth opportunities in data-center transactions and trust deposits. While residential market weakness and commercial real estate dependence pose risks, analysts project 17.7% EPS growth for 2026 and assign the stock a Zacks Rank #2 (Buy) rating with a 38.3% upside potential.Zacks Investment Research · Oct 15, 2026

Is a Beat in the Cards for W.R. Berkley This Earnings Season?W.R. Berkley Corporation is predicted to beat third-quarter 2026 earnings expectations with a +1.31% Earnings ESP and Zacks Rank #3. Insurance premiums are expected to grow 3.6% while reinsurance premiums may decline 0.9%. The combined ratio is estimated at 92.77%, supported by disciplined underwriting but pressured by elevated catastrophe losses from severe convective storms.Zacks Investment Research · Oct 14, 2026

RNR or TKOMY: Which Is the Better Value Stock Right Now?In a comparison of two insurance stocks, RenaissanceRe (RNR) emerges as the better value opportunity compared to Tokio Marine Holdings (TKOMY). RNR has a Zacks Rank of #2 (Buy) with a forward P/E of 7.49 and Value grade of B, while TKOMY has a Zacks Rank of #4 (Sell) with a forward P/E of 242.86 and Value grade of C. RNR's improving earnings outlook and superior valuation metrics make it the more attractive choice for value investors.Zacks Investment Research · Oct 12, 2026

FAF Stock Outperforms Industry: Time to Buy for Solid Returns?First American Financial (FAF) has outperformed its industry with an 18% year-to-date gain, driven by 34% commercial revenue growth, 30% increase in average deposits, and 140% surge in data-center revenues. The company is leveraging AI to improve operational efficiency and maintains strong financial flexibility with $2.6 billion in cash. Despite headwinds from a weak residential housing market, analysts project 17.5% EPS growth for 2026 with a consensus price target suggesting 20.6% upside.Zacks Investment Research · Sep 15, 2026

Why Is Mercury General (MCY) Down 6.1% Since Last Earnings Report?Mercury General (MCY) reported strong Q2 2026 earnings, beating consensus estimates with operating income of $3.52 per share (up 31.8% YoY) and revenues of $1.67 billion. The company benefited from premium growth, improved underwriting profitability with a combined ratio of 89.9%, and higher investment income. However, catastrophe losses surged to $75 million from $13 million YoY due to California wildfires and Texas/Oklahoma storms. Despite the strong results, MCY shares have underperformed the S&P 500 by 6.1% over the past month. The stock holds a Zacks Rank #1 (Strong Buy) rating.Zacks Investment Research · Sep 3, 2026

A Quiet Outperformer With a Catastrophe CaveatAxis Capital, a specialty insurer and reinsurer, delivered strong 2025 results with record premiums, record underwriting income, and a 19.4% annualized return on equity. The company's shift toward higher-margin specialty insurance lines is paying off, with the insurance segment now representing 74% of business. However, investors should be cautious as the stock has already had a significant run-up, and the company faces inherent risks from catastrophic events and competitive pressures that could erode margins.Investing.com · Apr 14, 2026

VedTechBio® Launches RxAgentAI™ – an Artificial Intelligence and Machine Learning Platform, catering to the decision making and strategic needs of stakeholders in the life sciences industry AND VedTechBio® Announces a Drug Discovery Collaboration with RenaissThera®VedTechBio, a biopharma-tech company, has launched RxAgentAI, an AI and ML platform for the life sciences industry. It has also announced a drug discovery collaboration with RenaissThera, a biotech company working on metabolic diseases.GlobeNewswire Inc. · Oct 16, 2024

Here's Why You Should Hold RenaissanceRe (RNR) Stock for NowRenaissanceRe (RNR) is expected to benefit from rising premiums, net investment income, and underwriting capabilities.Zacks Investment Research · Jun 27, 2024

W.R. Berkley (WRB) Boosts Shareholders' Value Via Several MovesImproved pricing, expansion of international business, reserving discipline, a solid balance sheet and a prudent capital management policy should help W.R. Berkley (WRB) maintain its streak of dividend hikes and special dividends.Zacks Investment Research · Jun 13, 2024

RNRRenaissanceRe Holdings Ltd.

RNR

Pay with—

Start Trading

Available Balance0.00

Your PositionYou don't own any RNR yet.

Related Tickers

Earnings

Dividends

Last · Sep 15Quarterly

Amount$0.41

Yield0.46%

Annual$1.63

Mkt Cap

$14.59B

Volume

239.32K

Next Earnings

October 27th